Alpha 2.0
Login Register
» Authors » Vimal H Prajapati

Vimal H Prajapati

Explore the profile of Vimal H Prajapati including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 67
Citations 285
Followers 0
Related Specialties
Dermatology
General Surgery
Pediatrics
Top 10 Co-Authors
Jensen Yeung
Abrahim Abduelmula
Ronald Vender
Brian D Rankin
Jorge R Georgakopoulos
Alim R Devani
Asfandyar Mufti
Siddhartha Sood
Khalad Maliyar
Ahmed Bagit
Published In
J Am Acad Dermatol
J Cutan Med Surg
Dermatol Ther (Heidelb)
JAAD Int
Pediatr Dermatol
Affiliations
Soon will be listed here.
Recent Articles
1.
Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial
Eichenfield L, Serrao R, Prajapati V, Browning J, Swanson L, Funk T, et al.
Pediatr Dermatol . 2025 Feb; PMID: 39980188
Background/objectives: Efficacy and safety of roflumilast cream 0.15% were demonstrated in patients aged ≥ 6 years with atopic dermatitis (AD) in two Phase 3 trials. This Phase 3 parallel-group, double-blind...
2.
Response to Potestio et al., "Comment on Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review"
Sood S, Rimke A, Rankin B, Abduelmula A, Georgakopoulos J, Maliyar K, et al.
J Am Acad Dermatol . 2025 Feb; PMID: 39955006
No abstract available.
3.
Management of Chronic Prurigo and Prurigo Nodularis with Systemic Janus Kinase Inhibitors: An Evidence-Based Review
Sood S, Geng R, Heung M, Maliyar K, Abduelmula A, Sachdeva M, et al.
J Cutan Med Surg . 2025 Feb; :12034754251320633. PMID: 39953906
No abstract available.
4.
Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a phase 2, randomized, placebo-controlled study
Ackerman L, Schlosser B, Zhan T, Prajapati V, Fretzin S, Takahashi H, et al.
J Am Acad Dermatol . 2025 Feb; PMID: 39909350
Background: Hidradenitis suppurativa is a disabling inflammatory skin disease. Objective: To investigate the efficacy and safety of upadacitinib, a selective Janus kinase inhibitor. Methods: In this phase 2, randomized, placebo-controlled,...
5.
Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective Study
Sood S, Rimke A, Rankin B, Abduelmula A, Georgakopoulos J, Maliyar K, et al.
Am J Clin Dermatol . 2025 Feb; 26(2):301-304. PMID: 39900871
No abstract available.
6.
Real-world experience of tralokinumab for atopic dermatitis: A 16-week multicenter retrospective study
Sood S, Wiseman M, Bagit A, Maliyar K, Sachdeva M, Abduelmula A, et al.
J Am Acad Dermatol . 2025 Jan; PMID: 39864749
No abstract available.
7.
Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 52-week multicenter retrospective review
Sood S, Rimke A, Rankin B, Abduelmula A, Georgakopoulos J, Maliyar K, et al.
J Am Acad Dermatol . 2025 Jan; PMID: 39831882
No abstract available.
8.
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial
Simpson E, Eichenfield L, Papp K, Forman S, Hebert A, Gonzalez M, et al.
Dermatitis . 2025 Jan; PMID: 39792455
Safety and efficacy of roflumilast cream 0.15% for atopic dermatitis (AD) were demonstrated in two 4-week phase 3 trials. Evaluate long-term safety, tolerability, and efficacy of roflumilast cream 0.15% in...
9.
Guselkumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients: results of the phase 3, randomized, placebo-controlled PROTOSTAR study
Prajapati V, Seyger M, Wilsmann-Theis D, Szakos E, Kaszuba A, van Hartingsveldt B, et al.
Br J Dermatol . 2024 Dec; PMID: 39708367
Background: No currently approved treatment for pediatric plaque psoriasis selectively targets interleukin (IL)-23. In adults, guselkumab (a selective IL-23 inhibitor targeting the p19 subunit) demonstrated substantial efficacy with a favorable...
10.
Effectiveness and Safety of Upadacitinib in Adolescent and Adult Patients with Atopic Dermatitis: An Analysis of Long-Term (Week 52) Data from a Real-World Multicenter Retrospective Review
Rankin B, Sood S, Park Y, Rimke A, Abduelmula A, Georgakopoulos J, et al.
Dermatitis . 2024 Oct; PMID: 39446652
No abstract available.